REG - Renalytix PLC - Change of Adviser

RenalytixAnnouncement

30/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240830:nRSd2027Ca&default-theme=true

RNS Number : 2027C  Renalytix PLC  30 August 2024

 

Renalytix plc

("Renalytix" or the "Company")

 

Change of Adviser

 

LONDON and NEW YORK, 30 August 2024 - Renalytix plc (NASDAQ: RNLX) (LSE:
RENX), an artificial intelligence-enabled in vitro diagnostics company,
focused on optimizing clinical management of kidney disease to drive improved
patient outcomes and advance value-based care, announces that with the
previously announced appointment of Oberon Capital (a trading name of Oberon
Investments Limited) as joint broker on August 21(st) concurrent with Stifel
Nicolaus Europe Limited ("Stifel"), that Investec Bank plc is ceasing to act
as Joint Broker with effect from 31 August 2024. Stifel will continue to act
as Nominated Adviser.

 

For further information, please contact:

 

 Renalytix plc                                    www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                            Via Walbrook PR

 Stifel (Nominated Adviser and Joint Broker)      Tel: 020 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Oberon Capital (Joint Broker)                    Tel: 020 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited                              Tel: 020 7933 8780 or renalytix@walbrookpr.com
 Paul McManus / Alice Woodings / Charlotte Edgar  Mob: 07980 541 893 / 07407 804 654 / 07884 664 686

 CapComm Partners
 Peter DeNardo                                    Tel: 415-389-6400 or investors@renalytix.com

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory
services company that is the global founder and leader in the new field of
bioprognosis™ for kidney health. The leadership team, with a combined 200+
years of healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D and early
CKD (stages 1-3). We believe that by understanding how disease will progress,
patients and providers can take action early to improve outcomes and reduce
overall health system costs. For more information, visit www.renalytix.com
(https://www.globenewswire.com/Tracker?data=ThoNM1PDWeVIxIN1XNvxXoh0EK3Og6d0k06ZfN9GrAjS1_QubydWs_nD7MTPteCUCpzWMT-T9VtSxqrwDhSDHeCPMgeDBf4ZA-6KeA6aJT4=)
.

 

Important Notices

Stifel Nicolaus Europe Limited and Oberon Investments Limited are authorised
and regulated in the United Kingdom by the Financial Conduct Authority
("FCA") and are acting exclusively for the Company and for no one else in
connection with the subject matter of this announcement and will not be
responsible to anyone other than Renalytix for providing the protections
afforded to its clients nor for providing advice in relation to the subject
matter of this announcement.

 

This announcement is not intended to, and does not, constitute or form part of
any offer, invitation or the solicitation of an offer to purchase, otherwise
acquire, subscribe for, sell or otherwise dispose of, any securities whether
pursuant to this announcement or otherwise.

 

This announcement (including any information incorporated by reference in this
announcement) and other information published by the Company contain
statements about the Company that are or may be deemed to be forward looking
statements. Without limitation, any statements preceded or followed by or that
include the words "targets", "plans", "believes", "expects", "aims",
"intends", "will", "may", "anticipates", "estimates", "projects" or words or
terms of similar substance or the negative thereof, may be forward looking
statements.

 

These forward-looking statements are not guarantees of future performance.
Such forward-looking statements involve known and unknown risks and
uncertainties that could significantly affect expected results and are based
on certain key assumptions. Many factors could cause actual results to differ
materially from those projected or implied in any forward-looking statements.
Due to such uncertainties and risks, readers should not rely on such
forward-looking statements, which speak only as of the date of this
announcement. The Company disclaims any obligation or responsibility to update
publicly or review any forward-looking or other statements contained in this
announcement, except as required by applicable law.

 

The distribution of this announcement in jurisdictions outside the United
Kingdom may be restricted by law and therefore persons into whose possession
this announcement comes should inform themselves about, and observe, such
restrictions. Any failure to comply with the restrictions may constitute a
violation of the securities law of any such jurisdiction.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPPLMJTMTATBAI